ACM
OTLK icon

Altium Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Altium Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-541,549
Closed -$2.89M – 88
2024
Q3 		$2.89M Buy
541,549
+39,764
+8% +$291K 0.85% 37
2024
Q2 		$3.7M Buy
+501,785
New +$4.03M 1.51% 25
2023
Q1 		– Sell
-166,370
Closed -$3.59M – 100
2022
Q4 		$3.59M Buy
+166,370
New +$3.62M 1.83% 20

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Altium Capital Management's OTLK Position: Q4 2024 in Review

Altium Capital Management sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 541,549 shares — an estimated $2.89M sold.

Altium Capital Management first reported a position in OTLK in Q4 2022 and held it in 3 quarters. The position peaked at $3.7M in Q2 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Altium Capital Management reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Altium Capital Management sold 541,549 Outlook Therapeutics shares in Q4 2024, an estimated $2.89M.
  • Altium Capital Management first reported a position in Outlook Therapeutics in Q4 2022 and held it in 3 quarters.
  • Altium Capital Management's Outlook Therapeutics position peaked at $3.7M in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.